US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Kazia Therapeutics Limited - American Depositary Shares (NQ:KZIA)

9.270 -0.200 (-2.11%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kazia Therapeutics Limited - American Depositary Shares

News headline image
Small-Cap Disruptors KZIA, SNYR, HSDT, TRNR, PRSO Lead Momentum – More Microcap Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
Kazia Therapeutics CEO talks $4.5 million capital raise
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner speaks with Proactive after confirming a two-tranche capital raising initiative to raise A$4.5 million through placements to... 
Via TheNewswire.com
News headline image
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
Via ACCESSWIRE
News headline image
Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
Via ACCESSWIRE
News headline image
Kazia Therapeutics (KZIA): Doubling Down on Clinical Development
Via ACCESSWIRE
News headline image
KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US
KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US Sydney, 20 July 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug... 
Via iCrowdNewswire
News headline image
Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer
LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address... 
From Edison Investment Research Limited
Via AccessWire
News headline image
Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential... 
From Edison Investment Research Limited
Via AccessWire
News headline image
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly... 
From Edison Investment Research Limited
Via AccessWire
News headline image
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for... 
From Edison Investment Research Limited
Via AccessWire